Rupjani B's Page

Hi !This is Rupjani, my son Anuran was diagnosed with DMD in 2010 when we are in Wisconsin . We were there from 2010 to 2013 , after that we returned to India . Once again , we are back in U.S. , this time in Chicago . I would like to connect with Chicago DMD families. My cell no is 224-201-5885.( 2pm to 4pm preferable ) Thanks in advance.See More

Nov 11th 2015, 1:00 pm ETJoin us Wednesday, November 11th at 1pm ET to learn more about the importance of myostatin inhibition research. This webinar will help to put context and clarity around this treatment pathway so families have a better understanding as they see clinical trials in this area. About Myostatin Inhibition: Scientists have long theorized that the body normally contains compounds that limit muscle growth. For example, certain breeds of cattle develop substantially more muscle…See More

I've just read Santhera FAQ family friendly version.It is written in question no 4 that:Currently, Santhera anticipates that the label sought will be restricted to patients who are not using steroids and who have signs of impaired respiratory function. Regulatory agencies often base the label upon the available data at hand and it should be kept in mind that all of the data collected in the idebenone phase III trial is from participants who were age 10 and older at the time. Santhera does…See More

Efficacy of Catena®/Raxone® (Idebenone) on Respiratory Outcome in Duchenne: Results of the phase 3 double-blind, randomized, placebo-controlled DELOS trialSanthera Pharmaceuticals presented data of the Phase III DELOS trial during a webinar hosted by Parent Project Muscular Dystrophy on Wednesday, October 15th at 12pm eastern. Presenters:Prof. Gunnar Buyse (University Hospitals Leuven, Belgium); PI of the studyThomas Meier PhD, CEO of…See More

The webinar will discuss the Phase 1 Clinical Trial results on SMT C1100 for the treatment of Duchenne as well as outlining the next steps for this utrophin upregulator program. Jon Tinsley, Senior Director of R&D and Richard Pye, Head of Communications at Summit plc will give a presentation and answer questions that have been submitted.Questions must be submitted by Friday, December 7 at noon eastern. If you have questions you would like to submit to…See More

Summit Corporation plc ('Summit' or 'the Company') REPEAT DOSING OF SMT C1100 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MEETS ENDPOINTS IN PHASE 1 CLINICAL TRIAL * New formulation delivers drug levels that are predicted to significantly increase utrophin production * Summit to progress utrophin upregulator into next stages of development Oxford, UK, 7 November 2012 - Summit (AIM: SUMM), a UK drug discovery company, announces that the repeat dosing of the utrophin upregulator SMT…See More